Harry Skip  Kiil net worth and biography

Harry Kiil Biography and Net Worth

EVP & President, Cardiovascular Portfolio of Medtronic

Harry “Skip” Kiil is Executive Vice President and President of Medtronic’s Cardiovascular Portfolio. He serves on the Medtronic Executive Committee and leads a global team focused on delivering transformative therapies across six operating units – Cardiac Ablation Solutions, Cardiac Rhythm Management, Cardiac Surgery, Coronary & Renal Denervation, Mechanical Circulatory Support, Peripheral Vascular Health, and Structural Heart and Aortic.

Skip has more than 20 years of global leadership experience in the medical technology industry. He is known for building high-performing teams, leading complex business transformations, and driving strong commercial and operational execution.

Prior to this role, Skip served as president of Medtronic’s Cranial & Spinal Technologies (CST) Operating Unit, where he led the business to record growth and helped establish CST as a $5 billion global leader. He was the architect of CST’s AiBLE™ strategy—a connected ecosystem of technology, data, and services that is redefining surgical care in spine and cranial procedures.

Before joining Medtronic, Skip held senior leadership roles at Smith+Nephew, NuVasive, Novartis, and Stryker. His experience spans global commercial operations, product innovation, manufacturing, and go-to-market strategy. He has led teams across the U.S., Europe, and Asia, with a focus on execution, accountability, and culture.

He is also deeply committed to improving access to care. During his time in CST, Skip launched a strategic partnership with Hall of Fame Health to expand access to specialized neurosurgical and spinal care for former athletes, U.S. veterans, and their families. While at Smith+Nephew, he helped initiate a similar partnership focused on expanding access to joint replacement care. These efforts reflect his broader commitment to closing care gaps and improving health equity through innovative industry collaboration.

Skip holds a Bachelor of Science in Kinesiology from California State University, Fullerton, and an MBA from the University of Michigan Ross School of Business.

What is Harry Skip Kiil's net worth?

The estimated net worth of Harry Skip Kiil is at least $3.63 million as of September 3rd, 2025. Mr. Kiil owns 35,615 shares of Medtronic stock worth more than $3,630,237 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Kiil may own. Learn More about Harry Skip Kiil's net worth.

How do I contact Harry Skip Kiil?

The corporate mailing address for Mr. Kiil and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Harry Skip Kiil's contact information.

Has Harry Skip Kiil been buying or selling shares of Medtronic?

Harry Skip Kiil has not been actively trading shares of Medtronic within the last three months. Most recently, Harry Skip Kiil sold 8,605 shares of the business's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a transaction totalling $788,045.90. Following the completion of the sale, the executive vice president now directly owns 35,615 shares of the company's stock, valued at $3,261,621.70. Learn More on Harry Skip Kiil's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Harry Kiil (EVP & President, Cardiovascular Portfolio), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (Chairman of the Board & CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, Medtronic insiders bought shares 2 times. They purchased a total of 5,000 shares worth more than $462,750.00. During the last year, insiders at the medical technology company sold shares 3 times. They sold a total of 30,892 shares worth more than $2,699,414.40. The most recent insider tranaction occured on September, 3rd when EVP Harry Skip Kiil sold 8,605 shares worth more than $788,045.90. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 9/3/2025.

Harry Skip Kiil Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/3/2025Sell8,605$91.58$788,045.9035,615View SEC Filing Icon  
See Full Table

Harry Skip Kiil Buying and Selling Activity at Medtronic

This chart shows Harry Skip Kiil's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $101.93
Low: $101.74
High: $102.75

50 Day Range

MA: $96.65
Low: $90.10
High: $105.32

2 Week Range

Now: $101.93
Low: $79.29
High: $106.33

Volume

4,480,486 shs

Average Volume

7,817,223 shs

Market Capitalization

$130.68 billion

P/E Ratio

27.47

Dividend Yield

2.79%

Beta

0.71